Verrica Pharmaceuticals Inc.
VRCA
$6.73
-$0.82-10.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 98.80% | 101.19% | 52.08% | 34.18% | 7.83% |
| Total Depreciation and Amortization | -46.20% | -40.42% | -38.82% | 16.59% | 62.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -37.35% | -59.79% | -43.52% | -20.84% | -70.78% |
| Change in Net Operating Assets | -28.01% | -385.45% | -82.64% | -184.06% | 4,021.71% |
| Cash from Operations | 213.17% | 38.60% | 36.45% | -10.73% | 42.22% |
| Capital Expenditure | -- | -- | -- | 100.00% | 75.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 103.52% | 75.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,735.94% | -2,247.46% | -2,500.64% | -1,526.09% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 5,500.00% | -195.08% |
| Cash from Financing | -903.53% | -549.22% | -513.77% | 146,122.22% | -100.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 163.55% | 16.52% | 18.80% | 258.32% | -130.76% |